IL15 and renal carcinoma: The low in vitro concentration used in this study is within the range for the maximal serum concentration achieved therapeutically in patients with metastatic malignant melanoma or renal cancer after a low-dose transfusion of 0.3 μg/kg/day recombinant human IL-15 and which resulted in increases in innate cytokines (23).